Adamas Pharmaceuticals
- Company typePublic
- Founded2000
- HeadquartersEmeryville, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Adamas Pharmaceuticals firmographics
Firmographics- Name
- Adamas Pharmaceuticals
- Legal name
- Supernus Pharmaceuticals, Inc.
- Website
- https://adamaspharma.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Adamas Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Adamas Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Emeryville
- HQ country
- United States
- HQ region
- North America
Markets served
Adamas Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Adamas Pharmaceuticals product offering
Product offeringCore offering
Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics targeting infectious diseases and central nervous system (CNS) disorders. The company applies proprietary drug formulation and pharmacokinetic engineering to create dosing regimens intended to improve adherence, symptom control, and clinical outcomes in chronic neurological and infectious disease indications.
Differentiator
Problem solved
Functional benefit
Brands
- Qelbree: FDA-approved product for the treatment of ADHD, a CNS condition.
Products and services
- Controlled release combination therapeutics for CNS and infectious diseases Therapeutic products engineered with controlled-release pharmacokinetics and combination drug approaches targeting infectious diseases and central nervous system disorders. Distributed to healthcare providers and through specialty pharmacy channels for patient use under prescription.
Companies that use Adamas Pharmaceuticals
Customer profileIdeal customer profiles1 record
Adamas Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Adamas Pharmaceuticals partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Adamas Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Neurocrine Biosciences: Public US specialty pharma focused on neurology and psychiatry products. Direct peer in CNS indication focus, specialty-pharma commercial model, and public-market scale.
- Jazz Pharmaceuticals: Public specialty pharma with a strong CNS/neurology franchise (including narcolepsy and epilepsy products). Comparable to Adamas in CNS therapeutic focus and specialty-pharma commercial scale.
- Acadia Pharmaceuticals: Specialty pharmaceutical company commercializing CNS therapies including treatments for Parkinson's disease psychosis and Rett syndrome. Overlaps Adamas on neurology indication targeting and specialty commercial model.
- Supernus Pharmaceuticals: Public CNS-focused specialty pharmaceutical company with marketed CNS products and a development pipeline. Highly comparable to Adamas on therapeutic area (CNS), commercial-stage business model, and specialty-pharma go-to-market.
- Sage Therapeutics: CNS-focused biopharmaceutical company developing therapies for CNS conditions (now part of Supernus). Direct peer on therapeutic-area focus and specialty CNS development model.
Broad incumbents
- Teva Pharmaceutical Industries: Large generic and specialty pharmaceutical company with a meaningful CNS portfolio including Parkinson's disease treatments. Comparable on CNS therapeutic area and combination/specialty-pharma business lines, but much broader in scale and product mix.
- Lundbeck: Global pharmaceutical company specializing exclusively in brain diseases including neurology and psychiatry. Comparable CNS-focused portfolio and specialty-pharma model, but operates as a broad incumbent across multiple CNS indications.
- Otsuka Pharmaceutical: Global pharmaceutical company with a CNS franchise (including psychiatry and neurology products). Overlaps Adamas in CNS specialty-pharma development and commercialization, but operates across many therapeutic areas.
- UCB: Global biopharmaceutical company with a significant neurology/CNS franchise (epilepsy, Parkinson's). Comparable CNS indication coverage, but at a larger, more diversified scale than Adamas.
Emerging players
- Inhibikase Therapeutics: Smaller clinical-stage biotechnology company developing therapeutics for CNS and infectious disease indications. Comparable on therapeutic-area overlap with Adamas (CNS + infectious disease), though at earlier stage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Adamas Pharmaceuticals social profiles
Digital presenceAdamas Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adamas Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Adamas Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Adamas Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adamas Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adamas Pharmaceuticals
What does Adamas Pharmaceuticals do?
Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics targeting infectious diseases and central nervous system (CNS) disorders. The company applies proprietary drug formulation and pharmacokinetic engineering to create dosing regimens intended to improve adherence, symptom control, and clinical outcomes in chronic neurological and infectious disease indications.
Is Adamas Pharmaceuticals a public or private company?
Adamas Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Adamas Pharmaceuticals founded?
Adamas Pharmaceuticals was founded in 2000. It employs 51 to 100 people.
Where is Adamas Pharmaceuticals based?
Adamas Pharmaceuticals is headquartered in Emeryville, United States, in the North America region.
Who are Adamas Pharmaceuticals's main competitors?
Direct peers on record are Neurocrine Biosciences, Jazz Pharmaceuticals, Acadia Pharmaceuticals, Supernus Pharmaceuticals and Sage Therapeutics. Broad incumbents are Teva Pharmaceutical Industries, Lundbeck, Otsuka Pharmaceutical and UCB. Inhibikase Therapeutics is listed as an emerging player.
Does Adamas Pharmaceuticals have an API?
No public API is recorded for Adamas Pharmaceuticals.
What industry is Adamas Pharmaceuticals in?
Adamas Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.